newsfilter
← Latest News
GlobeNewswire·

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast